November 16, 2022 10:51 AM ESTUpdated 11:24 AM
Deals

For $30M, Chi­nese bio­phar­ma Sim­cere picks up re­gion­al rights to Idor­sia’s in­som­nia drug

Lei Lei Wu

News Reporter

For a mod­est up­front of $30 mil­lion, Sim­cere is buy­ing re­gion­al rights for dari­dorex­ant, Idor­sia’s in­som­nia drug that’s mar­ket­ed as Qu­viviq in the US and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times